Get started
Work

Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma

Year: 2017
Type: article
DOI: 10.1093/annonc/mdx377.013
Authors: D. Schadendorf, K.T. Flaherty, P. Nathan, P. Hersey, C. Garbe, M. Milhem, L. Demidov, P. Mohr, J.C. Hassel, P. Rutkowski, R. Dummer, J. Utikal, F. Kiecker, J. Larkin, A. D’Amelio, Y. Huang, B. Mookerjee, C. Robert
Institutions: Essen University Hospital, Massachusetts General Hospital, Mount Vernon Cancer Centre, The University of Sydney, Universitätsklinikum Tübingen, University of Iowa, University of Iowa Hospitals and Clinics, Russian Cancer Research Center NN Blokhin, Elbe Kliniken Stade-Buxtehude, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, The Maria Sklodowska-Curie National Research Institute of Oncology, University Hospital Zurich, German Cancer Research Center, Charité – Universitätsmedizin Berlin, Royal Marsden Hospital, Novartis (United States), Inserm, Institut Gustave Roussy
Language: English
Open Access status: bronze
OpenAlex ID: W2762501084
FWCI:
Cites:
Cited by:
Related to: 10